Simulations Plus Releases GastroPlus Version 8.6
Interim release adds several user-requested functions
Simulations Plus Releases ADMET Predictor Version 7.1
Upgrade extends technological lead, adds several user-requested functions
Simulations Plus Announces Quarterly Cash Dividend
Cash dividend declared of $0.05 per share
Simulations Plus Provides Additional Details Regarding Cognigen Acquisition
Investor Conference Call Scheduled for Friday, July 25, at 1:15 PM PDT
Simulations Plus to Acquire Cognigen Corporation
A leading provider of clinical trial data analysis to expand company’s offerings
Simulations Plus Reports Third Quarter FY2014 Financial Results
Revenues up 20.9%, Net Income up 31.6%
Simulations Plus Sets Date for 3rd Quarter 2014 Earnings Release and Conference Call
Conference Call to be on Tuesday, July 8, at 4:15 PM ET
Simulations Plus Reports Preliminary Revenues for Third Fiscal Quarter FY2014
New All-time Record Revenues in Third Quarter
Simulations Plus Releases ADMET Predictor Version 7.0
Major upgrade improves all predictions, adds new ones
Simulations Plus Releases MedChem Studio Version 4.0 and MedChem Designer 3.0
Upgrades include powerful new optical structure recognition feature
Simulations Plus Announces Agreement with License Provider
Company Buys Out Perpetual Royalty Agreement
Simulations Plus Announces Quarterly Cash Dividend
Cash dividend declared of $0.05 per share
Simulations Plus Reports Second Quarter FY2014 Financial Results
Company completes 26th consecutive profitable quarter
Simulations Plus Sets Date for 2nd Quarter 2014 Earnings Release and Conference Call
Conference Call to be on Wednesday, April 9, at 4:15 PM ET
Simulations Plus Signs New Partnership Agreement in China
Research Institute for Liver Diseases to Offer Company’s Consulting Services
Simulations Plus Announces Success in COX-2/COX-1 Drug Design Project
Three of Four Molecules Hit Both Targets
Simulations Plus Reports Preliminary Revenues for Second Fiscal Quarter FY2014
Large Renewal Order Moves to Third Quarter, Still Posts Third Highest Quarterly Revenue
Simulations Plus Signs Research Collaboration Agreement with FDA
Company to Work with FDA on Mechanistic IVIVC Modeling